immatics receives €22 million final tranche of Series D fundraising

17-Jul-2014 - Germany

Immatics Biotechnologies GmbH announced that it has received €22m to complete a Series D financing round. The Company received €12m in October 2013 as an initial tranche of the total €34m funding round. The Series D funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, and AT Impf GmbH and others.

immatics will use this funding to complete the current phase 3 trial with its lead cancer vaccine IMA901 in patients with renal cell carcinoma (RCC). The trial is evaluating overall survival with IMA901 in combination with sunitinib (Sutent®, Pfizer), a current standard first-line therapy, compared with sunitinib alone in patients with metastatic and/ or locally advanced RCC. Following a planned interim analysis, the independent Data Safety Monitoring Board (DSMB) has recommended that the trial continues until completion. Final data from the study are expected in 2015. IMA901 is a rationally designed cancer vaccine comprising 10 different tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the majority of patients suffering from RCC.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?